Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.65 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.64 |
| ▸ | HPRT1 | P00492 | 4/20 | 0.38 |
| ▸ | TYMP | P19971 | 1/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.31 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.31 |
| ▸ | POLA1 | P09884 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2694580 | 0.98 | FGFR1 (0.65) | FGFR1SLC22A6HPRT1TYMPNT5E | |
| SCHEMBL2694577 | 0.88 | FGFR1 (0.52) | FGFR1SLC22A6HPRT1NT5ELMNA | |
| SCHEMBL2697250 | 0.85 | FGFR1 (0.49) | FGFR1SLC22A6NT5E | |
| Cidofovir Anhydrous SCHEMBL1389452 | 0.79 | FGFR1 (1.00) | FGFR1SLC22A6HPRT1TYMPNT5E | |
| Cidofovir Anhydrous SCHEMBL3948 | 0.79 | FGFR1 (1.00) | FGFR1SLC22A6HPRT1TYMPNT5E | |
| Cidofovir Anhydrous SCHEMBL151807 | 0.79 | FGFR1 (1.00) | FGFR1SLC22A6HPRT1TYMPNT5E | |
| Cidofovir Anhydrous SCHEMBL14682730 | 0.79 | FGFR1 (1.00) | FGFR1SLC22A6HPRT1TYMPNT5E | |
| SCHEMBL727570 | 0.79 | FGFR1 (0.55) | FGFR1SLC22A6HPRT1NT5EPOLB | |
| SCHEMBL2697253 | 0.78 | FGFR1 (0.44) | FGFR1SLC22A6LMNATHRBMTOR | |
| SCHEMBL2697249 | 0.78 | FGFR1 (0.44) | FGFR1SLC22A6LMNATHRBMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522932-B2 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2016-12-20 | — | — | US | disclosed |
| US-9249177-B2 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2016-02-02 | — | — | US | disclosed |
| US-20160009750-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2016-01-14 | — | — | US | disclosed |
| EP-1720890-B1 | PHOSPONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | LEUVEN K U RES & DEV (BE) | 2015-05-20 | — | — | EP | disclosed |
| US-20140316127-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2014-10-23 | — | — | US | disclosed |
| US-8809520-B2 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2014-08-19 | — | — | US | disclosed |
| US-20140039179-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2014-02-06 | — | — | US | disclosed |
| US-8501709-B2 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2013-08-06 | — | — | US | disclosed |
| US-20120108531-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2012-05-03 | — | — | US | disclosed |
| US-20070185062-A1 | Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140039179-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | PNP, NUDT1, TYMP | FGFR1 1742/4885SLC22A6 1224/4885HPRT1 13/4885 |
| US-20120108531-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | TYMP, PNP, NUDT1 | FGFR1 946/4885SLC22A6 3113/4885HPRT1 19/4885 |
| US-20070185062-A1 | Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | ENTPD5, PPA1, TYMP | FGFR1 1128/4885SLC22A6 1213/4885HPRT1 47/4885 |
| US-20160009750-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | PNP, NUDT1, TYMP | FGFR1 1742/4885SLC22A6 1224/4885HPRT1 13/4885 |
| US-20140316127-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | PNP, NUDT1, TYMP | FGFR1 1742/4885SLC22A6 1224/4885HPRT1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.